Phase
Condition
Colon Cancer; Rectal Cancer
Colon Cancer
Rectal Cancer
Treatment
ONCOSCREEN
Clinical Study ID
Ages > 18 All Genders
Study Summary
Eligibility Criteria
Inclusion
Inclusion Criteria:
- CRC Group
Signature of the informed consent indicating that the subject accepts toparticipate in the study and to comply with the requirements and restrictionsinherent in this study.
Subjects aged ≥18 years
Subject is willing to undergo FOBT test, colonoscopy, and tissue biopsy
Subject for whom the decision to perform a colonoscopy has been made by thetreating physician
Subject has positive CRC diagnosis according to colonoscopy result
Covered by a Health Insurance System
Subject is able to comply with all study procedures
- Control Group with risks and presence of polyps
Signature of the informed consent indicating that the subject accepts toparticipate in the study and to comply with the requirements and restrictionsinherent in this study.
Subjects aged ≥18 years
Otherwise healthy individuals with recognized risk factors for CRC developmentdefined by either heredity and/or obesity and/or smoking and/or excess alcoholconsumption and/or hyperlipidaemia.
Subject be willing to undergo FOBT test, colonoscopy, and tissue biopsy
Subject has negative CRC diagnosis according to colonoscopy result
Covered by a Health Insurance System, which will cover colonoscopy as screeningin patients with risk factors and alarm symptoms such as abdominal pain, changein stool texture, change in stool frequency, blood in stool/rectal bleeding,diarrhea, constipation, abdominal bloating, weight loss, tiredness.
- Control Group with risks and absence of polyps
Signature of the informed consent indicating that the subject accepts toparticipate in the study and to comply with the requirements and restrictionsinherent in this study.
Subjects aged ≥18 years
Otherwise healthy individuals with recognized risk factors for CRC developmentdefined by either heredity and/or obesity and/or smoking and/or excess alcoholconsumption and/or hyperlipidaemia.
Subject be willing to undergo FOBT test, colonoscopy, and tissue biopsy
Subject has negative CRC diagnosis according to colonoscopy result
Covered by a Health Insurance System, which will cover colonoscopy as screeningin patients with risk factors and alarm symptoms such as abdominal pain, changein stool texture, change in stool frequency, blood in stool/rectal bleeding,diarrhea, constipation, abdominal bloating, weight loss, tiredness.
- Control Group with no risks
Signature of the informed consent indicating that the subject accepts toparticipate in the study and to comply with the requirements and restrictionsinherent in this study.
Subjects aged ≥40 years
Otherwise healthy individuals without any recognized risk factors for CRCdevelopment defined by either heredity and/or obesity and/or smoking and/orexcess alcohol consumption and/or hyperlipidemia.
Subject be willing to undergo FOBT test
Subject has negative FOBT result
Exclusion
Exclusion Criteria:
- For the CRC Group
Legal incapacity or limited legal capacity
Subject did not sign the Informed Consent form
Subject who, according to the investigator's assessment, presents with anunstable medical condition contraindicating the performance of the plannedblood test, stool test or breath test
Subject has had surgery in the previous 6-8 weeks or is under medication forCRC treatment.
- For the control groups
Legal incapacity or limited legal capacity
Subject did not sign the Informed Consent form
Previous history of any type of cancer
Gastrointestinal disorders or other serious acute or chronic diseases
Study Design
Study Description
Connect with a study center
University Specialised Hospital for Active Treatment of Oncology Departement of Gastroenterology.
Sofia, 1797
BulgariaSite Not Available
Military Medical Academy Sofia, Gastroenterology Clinic, 3 Sveti Georgi Sofiiski str., Sofia 1606, Bulgaria
Sofia 727011, 1606
BulgariaActive - Recruiting
University Specialised Hospital for Active Treatment of Oncology Departement of Gastroenterology.
Sofia 727011, 1797
BulgariaSite Not Available
Masaryk Institute of Oncology
Brno, 656 53
CzechiaSite Not Available
UFC: Université de Franche-Comté Oncology department CHU Besançon
Besançon, 25030
FranceSite Not Available
UFC: Université de Franche-Comté Oncology department CHU Besançon
Besançon 3033123, 25030
FranceSite Not Available
MKI UKSH Lübeck
Lübeck, 23538
GermanySite Not Available
MKI UKSH Lübeck
Lübeck 2875601, 23538
GermanyActive - Recruiting
UMC Mainz: University Medical Center Mainz
Mainz-GE, 55131
GermanySite Not Available
UMC Mainz: University Medical Center Mainz
Mainz-GE 8224626, 55131
GermanyActive - Recruiting
LSMU: Lithuanian University of Health Sciences Gastroenterology Department,
Kaunas, 50161
LithuaniaSite Not Available
LSMU: Lithuanian University of Health Sciences Gastroenterology Department,
Kaunas 598316, 50161
LithuaniaActive - Recruiting
IPO: Instituto Português de Oncologia
Porto, 4200-072
PortugalSite Not Available
IPO: Instituto Português de Oncologia
Porto 2735943, 4200-072
PortugalActive - Recruiting
IBO: Institutul Oncologic Prof. Dr. Alexandru Trestioreanu București
Bucharest,
RomaniaSite Not Available
IBO: Institutul Oncologic Prof. Dr. Alexandru Trestioreanu București
Bucharest 683506,
RomaniaSite Not Available

Not the study for you?
Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.